Acasti Pharma (ACST) Reports Q1 Loss of $0.18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts ACST Hot Sheet
Join SI Premium – FREE
Acasti Pharma (NASDAQ: ACST) reported Q1 EPS of ($0.18), versus ($0.21) reported last year. Revenue for the quarter came in at $21 thousand, versus $178 thousand reported last year.
For earnings history and earnings-related data on Acasti Pharma (ACST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JetBlue Airways (JBLU) Misses Q3 EPS by 6c, Misses on Revenue
- FirstSun Capital Bancorp (FSUN) Tops Q3 EPS by 6c
- Volaris (VLRS) Tops Q3 EPS by 27c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
